Effector T cells mediate protective tumor immunity. The goal of tumor immune therapy including check-point blockade and immune vaccination and adoptive effector T cell is to engender long-term protective effector T cell immunity, and cause tumor eradiation in patients with cancer. To this end, effector T cells must traffic into and retai within the tumor microenvironment. Interestingly, the central scientific efforts in the field of tuor immunology are focused on exploring, designing and determining the functional potency and therapeutic efficacy of effector T cells. However, our current knowledge of effector T cell tumor trafficking and retention, and its underlying molecular mechanisms remain poorly understood in patients with cancer. This inadvertent deficiency significantly tempers our efforts toward understanding basic human effector T cell biology, establishing and evaluating immune therapeutic regimens and tumor vaccines in treating patients with cancer. It is essential to conduct comprehensive molecular and functional research on the nature of effector T cell tumor trafficking in the human tumor microenvironment. Th1-type chemokines CXCL9 and CXCL10 mediate effector T cell migration. CXCL9 and CXCL10 have been shown to be correlated with T cell density in human tumor and are associated positively with cancer patient survival. It is well known that IFN? stimulates the production of CXCL9 and CXCL10 in variety of cells. However, it is poorly understood how Th1-type chemokine expression is regulated in the human cancer microenvironment, and in turn how effector T cell tumor trafficking are controlled. Epigenetic silencing including histone modifications is important tumorigeneic mechanism in cancer. However, its role in tumor immunity remains to be defined. Using human primary ovarian cancer as a model, our preliminary studies demonstrated that a polycomb complex 2 (PRC2) protein, enhancer of zeste 2 (EZH2)-based histone H3 lysine 27 trimethylation (H3K27me3) was selectively involved in the regulation of the tumor production of Th1-type chemokines CXCL9 and CXCL10, and might subsequently determine effector T cell trafficking to the tumor microenvironment. Based on this surprising and novel finding, we hypothesize that tumor epigenetic silencing is not only a crucial carcinogeneic mechanism, but also key circuits controlling Th1-type chemokine expression and consequently impact effector T cell tumor trafficking and tumor therapy. We propose two specific aims to mechanistically, functionally and clinically test our central hypothesis.
Aim 1 is to test our hypothesis that PRC2-signaling circuit controls Th1-type chemokine production in the tumor microenvironment.
Aim 2 is to test our hypothesis that PRC2-signaling circuit clinically and therapeutically associates with effector T cell tumor trafficking and tumor immunity.

Public Health Relevance

In this proposal we focus on the patients with ovarian cancer. We study the immunological mechanisms by which effector T cell trafficking into the tumor. The study will potentially lead to the development of preventive or therapeutic agents for patients with cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Transplantation, Tolerance, and Tumor Immunology Study Section (TTT)
Program Officer
Mccarthy, Susan A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Schools of Medicine
Ann Arbor
United States
Zip Code
Crespo, Joel; Wu, Ke; Li, Wei et al. (2018) Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol 201:814-820
Hu, Xiao; Majchrzak, Kinga; Liu, Xikui et al. (2018) In Vitro Priming of Adoptively Transferred T Cells with a ROR? Agonist Confers Durable Memory and Stemness In Vivo. Cancer Res 78:3888-3898
Lin, Heng; Wei, Shuang; Hurt, Elaine M et al. (2018) Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest 128:1708
Li, Wei; Tanikawa, Takashi; Kryczek, Ilona et al. (2018) Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. Cell Metab 28:87-103.e6
Wang, Weimin; Zou, Weiping; Liu, J Rebecca (2018) Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy. Gynecol Oncol 151:1-3
Li, J; Xi, Y; Li, W et al. (2017) TRIM28 interacts with EZH2 and SWI/SNF to activate genes that promote mammosphere formation. Oncogene 36:2991-3001
Nagarsheth, Nisha; Wicha, Max S; Zou, Weiping (2017) Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol 17:559-572
Fang, Min; Li, Yongkui; Huang, Kai et al. (2017) IL33 Promotes Colon Cancer Cell Stemness via JNK Activation and Macrophage Recruitment. Cancer Res 77:2735-2745
Bitler, Benjamin G; Wu, Shuai; Park, Pyoung Hwa et al. (2017) ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat Cell Biol 19:962-973
Maj, Tomasz; Wang, Wei; Crespo, Joel et al. (2017) Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol 18:1332-1341

Showing the most recent 10 out of 23 publications